Laurus Labs Ltd (NSE: LAURUSLABS, BSE: 540222) – Comprehensive Equity Research Analysis

Laurus Labs Ltd (NSE: LAURUSLABS, BSE: 540222) – Comprehensive Equity Research Analysis

(Data as of approximately 18 September 2026 close; latest quarterly results for Q1 FY27 ended 30 June 2026. All figures in ₹ crore unless noted. Sources prioritise company filings, NSE/BSE, investor presentations and annual reports. Some secondary ratios vary slightly by provider; primary reported figures are used where available. No invented numbers.)

1. QUICK STOCK SNAPSHOT

• Current share price: ₹1,954 (NSE close ~18 Sep 2026)

• Today’s change %: +0.30% (₹+5.90)

• Market capitalisation: ~₹1,05,577 Cr (mid-cap)

• 52-week high / low: ₹1,982 / ₹823.10

• P/E ratio (TTM): ~96.9–118.8 (varies by source; trailing around 97–119x)

• P/B ratio: ~19.9

• ROE: ~18.2%

• ROCE: ~18.1% (some sources note higher trailing/recent figures around 19–24%)

• Debt-to-equity: 0.45

• Dividend yield: 0.10%

• Face value: ₹2

• Industry/sector: Pharmaceuticals (API, FDF, CDMO, Biotech)

2. COMPANY OVERVIEW

Laurus Labs is a research-driven Indian pharmaceutical and biotech company founded in 2005 (Hyderabad-based). It develops and manufactures Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs/generics), and provides Contract Development and Manufacturing Organisation (CDMO) services.

Main products/services: APIs (including ARV/antiretroviral, oncology, other intermediates), generic formulations (FDF), CDMO (small molecules, bio), and emerging biotech/enzyme solutions.

Major business segments:

• CDMO (fastest-growing; small molecules + bio)

• Affordable Medicines/Generics (API + FDF)

Key revenue sources: CDMO commercial projects and late-stage supplies; Generics (API + FDF, with ARV still material but declining in mix).

Geographic presence: Global (exports significant; manufacturing primarily in India – Vizag and other sites).

Important subsidiaries/units: Includes Laurus Generics entities and biotech-related units; focus on integrated offerings.

Competitive position: Strong in ARV APIs historically; transitioning successfully toward higher-value CDMO with commercial project ramp-up, capacity expansion in peptides, fermentation, ADCs/gene therapy. Competes with players like Divi’s Laboratories in specialty APIs/CDMO space.

3. LATEST QUARTERLY RESULT (Q1 FY27 – quarter ended 30 June 2026)

• Revenue: ₹2,026 Cr

• EBITDA: ₹644 Cr

• EBITDA margin: 31.8%

• Profit before tax (PBT): ₹481 Cr

• Net profit/PAT: ₹368 Cr (attributable ~₹362–368 Cr range in filings)

• EPS (diluted): ₹6.8

Comparisons:

• YoY (vs Q1 FY26 ₹1,570 Cr revenue / ₹163 Cr PAT / 24.8% EBITDA margin): Revenue +29%, EBITDA +66%, PAT +126%, EPS +127%. Gross margins expanded to 62.7% (+3.3 ppt).

• QoQ (vs Q4 FY26 ₹1,812 Cr revenue / ~₹279–282 Cr PAT / 28.9% EBITDA margin): Revenue +12%, EBITDA +23%, PAT +~32%.

Drivers: Strong CDMO growth (₹870 Cr, +67% YoY / +48% QoQ) from commercial projects and late-stage supplies; steady Generics (₹1,156 Cr, +10% YoY) led by FDF (+22%). Better mix, operational leverage, and process improvements drove margin expansion. Capex continued at ~19% of sales.

4. LAST 5 QUARTERS PERFORMANCE

Quarter | Revenue | EBITDA | Net Profit | EPS | YoY Revenue Growth | YoY Profit Growth

Q1 FY27 (Jun 26) | 2,026 | 644 | 368 | 6.8 | +29% | +126%

Q4 FY26 (Mar 26) | 1,812 | 523 | ~279–282 | ~5.2 | +5% | +19%

Q3 FY26 (Dec 25) | 1,778 | ~485 | 253 | 4.7 | +26% | Strong

Q2 FY26 (Sep 25) | 1,653 | ~403 | 194 | 3.6 | +35% | Strong

Q1 FY26 (Jun 25) | 1,570 | 389 | 163 | 3.0 | +31% | Very strong

(Approximate EBITDA/Net Profit for intermediate quarters from aggregated sources; primary company numbers prioritised for Q1 FY27 and FY ends. Trend is sequential improvement in scale and margins.)

Overall trend: Clear recovery and acceleration since FY25 trough. Revenue and profitability rising with CDMO mix shift; margins expanding on operating leverage. Strong YoY growth sustained into FY27.

5. 5-YEAR FINANCIAL PERFORMANCE

Financial Year | Revenue | Net Profit | EPS | ROE | ROCE | Debt (approx. total/net)

FY26 (Mar 26) | 6,813 | 889–890 | 16.4–16.5 | ~18% | ~17.7–18% | Total ~2,518; Net ~2,285

FY25 (Mar 25) | 5,554 | 358 | 6.6 | Lower | ~9.7% | Higher (~2,693)

FY24 (Mar 24) | 5,041 | ~161 | ~3.0 | Low | ~6–10% | ~2,577

FY23 (Mar 23) | 6,041 | ~790 | ~14.6 | Higher | High | Lower relative

FY22 (Mar 22) | 4,936 | ~828 | ~15.4 | High | High | —

CAGR (approx., reliable periods): Revenue FY22–FY26 ~8–9% (dip then recovery); stronger recent (FY25–26 +23%). Profit highly volatile (sharp drop FY24, strong rebound FY25–26).

Trend explanation: Growth and profitability weakened in FY24 (mix, utilisation, ARV softness, high capex drag) then improved markedly in FY25–26 with CDMO ramp, better mix, operating leverage and margin expansion. ROE/ROCE recovering. Debt moderated relative to EBITDA.

6. BALANCE SHEET & CASH FLOW

• Total debt: ~₹2,518 Cr (FY26); net debt ~₹2,285 Cr.

• Cash/cash equivalents: ~₹113 Cr (plus other bank balances).

• Debt trend: Declining net debt and net debt/EBITDA (to ~1.3x from 2.3x) despite growth capex. D/E improved to 0.45.

• Operating cash flow: ₹1,624 Cr in FY26 (strong +170% YoY).

• Free cash flow: Positive after capex (OCF covered elevated investments; FCF improved).

• Working capital: Elevated (inventories + receivables significant); typical for pharma/CDMO but monitored.

• Interest coverage: Comfortable (improving with higher EBITDA; ~10x range in some metrics).

• Major capex: ₹1,070 Cr in FY26; continuing high (Q1 FY27 ₹394 Cr / 19% of sales). Focus on capacity, peptides, fermentation, advanced therapies.

• Ability to service debt: Strong – rising OCF, declining leverage, healthy coverage. Self-funding growth well.

7. VALUATION ANALYSIS

• Current P/E: ~97–119x TTM (elevated).

• Historical P/E: Lower in growth years; compressed during FY24 trough; currently premium.

• Industry/peer P/E: Pharma/CDMO peers often lower (sector ~45–53x; Divi’s higher but typically below current Laurus multiple in some comparisons).

• P/B: ~19.9 (premium).

• EV/EBITDA: Elevated (sources ~50x+ range).

• PEG: ~1.9 in some calculations (growth-adjusted still premium).

Current valuation is significantly above historical averages and many peers, reflecting high expectations for sustained CDMO growth, margin expansion and capacity utilisation. Premium is growth-dependent.

8. PEER COMPARISON

Company | Market Cap (₹ Cr) | P/E | ROE | ROCE | Debt/Equity | Sales Growth | Profit Growth

Laurus Labs | ~1,05,577 | ~97–119 | ~18% | ~18% | 0.45 | Strong (recent 23%+) | Very strong

Divi’s Laboratories | ~2,48,877 | ~97 | ~16% | ~22% | Low | Moderate | Solid

Sun Pharma | ~4,40,830 | ~38 | ~15% | ~21% | Low | Steady | Moderate

Torrent Pharma | ~1,84,000 | ~85–90 | Higher | ~20% | Moderate | Good | Solid

Zydus Lifesciences | ~1,16,000 | ~23 | ~20% | ~23% | Low | Moderate | Moderate

Key differences: Laurus trades at a high multiple on faster recent growth and CDMO transition potential but has higher leverage historically and more volatility than pure-play specialty peers like Divi’s. Larger diversified players (Sun, Zydus) offer stability at lower valuations. Laurus’s ROE/ROCE recovering toward peer levels.

9. SHAREHOLDING PATTERN (as of Jun 2026)

• Promoters: 27.47% (stable/slight decline from 27.49% Mar 2026)

• FII/FPI: 28.00% (up from 25.82%)

• DII: 13.73–13.74% (slight change from ~14%)

• Mutual Funds: Included in DII; significant holdings in healthcare/index funds

• Public/Others: ~30.8%

QoQ change: FII increased notably; promoter stable; public slightly lower.

Promoter pledging: Limited/low (reports around 2.7% or not material in recent data; confirm latest filings).

10. DIVIDEND & CORPORATE ACTIONS

• Recent dividends: FY26 – Interim ₹0.80 (Oct 2025) + ₹1.20 (May 2026) = ₹2.00 total. Prior years lower (e.g., ₹1.20–1.60 range).

• Dividend history: Consistent interim payouts; yield low (~0.1%) due to growth focus and high price. Payout ratio modest (~10–15%).

• Bonus issues: None recent.

• Stock splits: 1:5 (₹10 to ₹2 face value) in Sep 2020.

• Buybacks / Rights: None material recent.

Focus remains on growth reinvestment.

11. LATEST NEWS & DEVELOPMENTS (last 30–90 days / relevant 2026)

Confirmed company/exchange:

• Q1 FY27 results (24 Jul 2026) – record revenue/EBITDA/PAT, strong CDMO.

• Capex guidance raised (FY27 ~₹2,000 Cr; cumulative ~₹3,000 Cr over FY27–28) for capacity (Unit 7, peptides, fermentation, ADCs, gene therapy).

• Land handover progress (large Vizag parcel).

• In-licensing of 2 ADC assets (Aarvik Therapeutics) for India.

• Continued capacity commissioning plans.

Media/analyst: Brokerages (e.g., Motilal Oswal) remain positive on CDMO momentum and raised estimates; stock near 52-week highs on results and outlook. No major negative regulatory or litigation flags in recent coverage.

12. ORDER BOOK / FUTURE BUSINESS

No single large disclosed “order book” figure (typical for CDMO mix of development + commercial). Healthy pipeline of late-stage/commercial projects driving CDMO.

Capacity expansion: Ongoing/high – Unit 7 (reactor capacity), fermentation (end-CY26 target), peptides, formulations JV, new sites. Capex intensity high (15–19% of sales).

New products/areas: ADCs, gene therapy, peptides, animal health, crop science (non-pharma diversification).

Management guidance: Sustained growth momentum, margin improvement via mix/leverage; capacity to support multi-year demand. Timelines: key blocks validation/commercialisation through FY27–28.

13. TECHNICAL ANALYSIS (as of ~18 Sep 2026)

• Current price: ₹1,954

• 20 DMA: ~₹1,899

• 50 DMA: ~₹1,793

• 100 DMA: ~₹1,579

• 200 DMA: ~₹1,309

• RSI (14): ~62 (neutral-bullish, not overbought)

• MACD: Positive but below/near signal in some readings (momentum positive overall)

• Volume trend: Supportive on recent moves

• Major support: ~₹1,900–1,910 / lower ~₹1,860–1,790 (DMAs)

• Major resistance: ₹1,982 (52W high) / psychological ₹2,000+

• Recent levels: Near all-time/52W high; strong uptrend from lows

• 52-week position: Near high (~top of range)

Classification: Bullish. Price above all major DMAs (20/50/100/200), RSI supportive of uptrend, strong momentum score in technical screens, sequential higher highs/lows. Near-term consolidation possible near resistance.

14. BULL CASE (5 evidence-based factors)

1. Sustained CDMO commercial project ramp and mix shift (higher margins).

2. Capacity expansion commissioning supporting multi-year volume growth.

3. Margin expansion via operating leverage and better product mix (already visible at 30%+ EBITDA).

4. Improving balance sheet (falling net debt/EBITDA, strong OCF).

5. Pipeline in high-value areas (peptides, ADCs, fermentation, gene therapy) and diversification.

15. BEAR CASE (5 major risks)

1. High valuation leaves limited room for execution misses or delays in capacity utilisation.

2. Continued high capex could pressure free cash flow/working capital if revenues lag.

3. Customer concentration or project delays in CDMO (common industry risk).

4. Regulatory/pricing pressures in generics/ARV or global pharma outsourcing slowdown.

5. Macro (currency, interest rates) or industry competition intensifying in specialty CDMO.

16. CATALYSTS TO WATCH

• Q2 FY27 results

• Capacity commissioning/validation (Unit 7, fermentation, peptides)

• Major commercial order/project announcements or offtake ramp

• Further guidance on multi-year growth/margins

• Debt trajectory and FCF improvement

• ADC/gene therapy progress and non-pharma scale-up

• Industry CDMO demand trends

17. INVESTOR CHECKLIST

Factor | Current Situation | What to Monitor

Revenue Growth | Strong (Q1 +29% YoY) | Sustainability of CDMO momentum

Profit Growth | Very strong (PAT +126% YoY) | Margin durability

Margins | Expanding (EBITDA 31.8%) | Mix and utilisation

ROE/ROCE | Recovering (~18%) | Further improvement with scale

Debt | Improving (D/E 0.45, net debt/EBITDA ~1.3x) | Absolute levels amid capex

Cash Flow | Strong OCF | FCF after elevated capex

Valuation | Premium | Earnings delivery vs expectations

Shareholding | FII rising, promoter stable | Institutional flows

Business Outlook | Positive on CDMO/capacity | Execution on expansion timelines

Technical Trend | Bullish (above key DMAs) | Break of support or new highs

18. FINAL SUMMARY

Laurus Labs has staged a strong recovery with accelerating revenue, sharp profit growth and expanding margins driven by CDMO commercialisation and operating leverage in FY26–Q1 FY27. Financial health is improving (stronger cash flows, moderating leverage) despite ongoing high growth capex. Valuation is rich relative to history and many peers, pricing in continued successful execution. Technically the stock is in a clear uptrend near highs. Key catalysts centre on capacity ramp and sustained CDMO momentum; biggest risks are execution delays, high expectations and any slowdown in high-value project flow. Balanced view: positive operational trajectory at a premium valuation.

19. BLOG CONTENT

SEO Title: Laurus Labs Stock Analysis 2026: Strong CDMO Growth, Expanding Margins & Outlook

Meta description: Complete data-driven analysis of Laurus Labs – Q1 FY27 results, 5-year financials, valuation, peers, technicals, bull/bear cases and key catalysts (updated Sep 2026).

Suggested Blogger URL slug: laurus-labs-stock-analysis-2026-cdmo-growth-outlook

10 SEO keywords: Laurus Labs share price, Laurus Labs quarterly results, LAURUSLABS analysis, Laurus Labs CDMO, Laurus Labs financials, Laurus Labs valuation, Laurus Labs peers, Laurus Labs technical analysis, Laurus Labs news, Indian pharma stocks

Blogger labels: Stock Analysis, Pharmaceuticals, CDMO, Equity Research, Indian Stocks, Laurus Labs

Facebook post hook: Laurus Labs just delivered record quarterly numbers with 29% revenue growth and margins at 32%. Is the CDMO story fully priced in? Full breakdown inside.

5 headline options:

1. Laurus Labs Q1 FY27: Record Revenue & 126% Profit Jump – What’s Next?

2. Why Laurus Labs Stock Surged: CDMO Momentum Explained

3. Laurus Labs at 52-Week High – Bull vs Bear Case 2026

4. Complete Laurus Labs Financial Analysis: Growth, Debt & Valuation

5. Laurus Labs Capacity Expansion & Pipeline – Key Catalysts for Investors

(Full ~1,500–2,000 word article would expand each section above into readable prose with short paragraphs, embedded tables and clear H2/H3 headings while remaining original and SEO-friendly. Core data and structure already provided.)

20. INFOGRAPHIC DATA

LAURUS LABS

Current Price: ₹1,954

Market Cap: ~₹1,05,577 Cr

52W High: ₹1,982

52W Low: ₹823

Latest Revenue (Q1 FY27): ₹2,026 Cr

Latest Profit (Q1 FY27): ₹368 Cr

Revenue Growth (YoY): +29%

Profit Growth (YoY): +126%

P/E: ~97–119x

ROE: ~18.2%

ROCE: ~18%

Debt/Equity: 0.45

Promoter Holding: 27.47%

FII Holding: 28%

Key Support: ~₹1,900 / 50 DMA

Key Resistance: ₹1,982 / ₹2,000

Technical Trend: Bullish

Main Growth Catalyst: CDMO commercial ramp + capacity commissioning

Biggest Risk: High valuation + execution on elevated capex

SOURCES (primary prioritised; dates approximate to access/publication):

• Company Q1 FY27 Press Release & Investor Presentation / NSE filings (24 Jul 2026)

• FY26 Annual Report & Results Presentation / company IR (Apr–Jun 2026)

• NSE/BSE announcements and shareholding patterns (Jun 2026 quarter)

• Company website investor section (lauruslabs.com)

• Aggregated market data (ET Money, ICICI Direct, Trendlyne, StockAnalysis, etc., as of mid-Sep 2026) for price/ratios/technicals

• Secondary: Economic Times, Motilal Oswal notes, Equitymaster for cross-checks

Reported facts drawn from official results and filings; ratios, growth rates and interpretations are calculated or synthesised from those figures. Always verify latest filings for trading decisions. This is not investment advice.

```